Enalapril Uses: High Blood Pressure and Heart Failure

Enalapril is a prescription medication used primarily to treat high blood pressure and heart failure, two conditions that together affect hundreds of millions of people worldwide. It belongs to a class of drugs called ACE inhibitors, and its track record in large clinical trials stretches back to the 1980s, when landmark studies showed it could cut death rates in severe heart failure by roughly a third. Beyond these two headline uses, enalapril has also shown kidney-protective effects in people with diabetes and is sometimes prescribed after a heart attack to limit further damage to the heart muscle.

How Enalapril Lowers Blood Pressure

Enalapril is a prodrug, meaning it is not active when you swallow it. Your liver converts it into enalaprilat, the form that actually does the work.¹ Enalaprilat blocks an enzyme called angiotensin-converting enzyme (ACE). That enzyme normally converts a relatively inactive molecule, angiotensin I, into angiotensin II, a powerful constrictor of blood vessels. By blocking that conversion, enalapril relaxes blood vessels and lowers the resistance your heart pumps against.

There is a second pathway that matters. ACE also breaks down bradykinin, a molecule that widens blood vessels and lowers blood pressure on its own. When enalapril blocks ACE, bradykinin hangs around longer and amplifies the blood-pressure-lowering effect.² This dual action is one reason ACE inhibitors can be particularly effective: they both shut down a system that raises pressure and boost a system that lowers it. The practical result is a drop in peripheral vascular resistance without the reflex jump in heart rate that some other blood-pressure drugs cause.³

Evidence in Heart Failure

Enalapril’s reputation was cemented by two large trials that fundamentally changed how doctors treat heart failure. The first, known as CONSENSUS, enrolled patients with the most severe form of heart failure. At six months, the death rate was about 26 percent in the enalapril group compared with 44 percent in those receiving a placebo, a roughly 40 percent reduction. At one year the mortality reduction was about 31 percent.⁴ For a population that was dying at alarming rates despite existing therapy, this was a dramatic improvement.

The second major trial, SOLVD, looked at a broader group of patients with reduced heart function. Among those with symptomatic heart failure, about 35 percent of the enalapril group died during follow-up compared with roughly 40 percent on placebo, a 16 percent reduction in the risk of death. Hospitalizations for worsening heart failure dropped by about 26 percent.⁵ These numbers made ACE inhibitors a standard part of heart failure treatment, and they remain so today.

How Enalapril Protects the Failing Heart

The survival benefit in heart failure is not just about lowering blood pressure. After a heart attack or during chronic heart failure, the heart undergoes a process called remodeling: the damaged or overworked ventricle gradually stretches, thins, and becomes less efficient. Enalapril appears to slow or partly reverse this remodeling. In the SOLVD echocardiography substudy, patients on placebo showed progressive increases in the volume and mass of the left ventricle, while those on enalapril did not.⁶ The drug reduced dilation and limited further thickening of the heart wall, which likely explains a large part of the survival benefit.

After an acute heart attack, similar protective effects have been observed. Enalapril limited infarct expansion, thinning, and progressive dilation of the ventricle during healing, and it improved the heart’s pumping efficiency.⁷ In a head-to-head comparison with losartan (an ARB, a different type of blood-pressure drug that targets the same hormonal system from a different angle), enalapril suppressed post-heart-attack remodeling more effectively.⁸

Starting Early, Before Symptoms Appear

One of the more forward-looking findings from the SOLVD program involved a separate group of patients who had weakened hearts (ejection fraction below 35 percent) but had not yet developed noticeable symptoms of heart failure. In that prevention arm, enalapril significantly reduced the number who went on to develop full-blown heart failure and cut hospitalizations related to it.⁹ There was also a trend toward fewer cardiovascular deaths, though it didn’t quite reach statistical significance.¹⁰

The practical takeaway: ACE inhibitors became first-line therapy even in early-stage heart failure with minimal or no symptoms. Imaging studies confirmed that even in asymptomatic patients, enalapril slowed the gradual stretching of the ventricle, although the pace of that stretching was slower to begin with than in symptomatic patients.¹¹

Kidney Protection in Diabetes

High blood pressure and diabetes together accelerate kidney damage. Enalapril has shown a protective effect that goes beyond simply lowering blood pressure. In a study comparing enalapril with the beta-blocker metoprolol at blood-pressure reductions that were otherwise equal, the kidney-function decline was substantially slower in the enalapril group: about 2 ml/min per year versus nearly 6 ml/min per year. Urinary albumin excretion, a marker of kidney damage, was about 60 percent lower with enalapril.¹² This suggests that enalapril’s benefits to the kidney are at least partly independent of blood-pressure control, likely because blocking ACE inside the kidney changes the pressure dynamics within the tiny blood-filtering units themselves.

Side Effects Worth Knowing About

Enalapril is generally well tolerated, but it carries a few side effects that are worth understanding, partly because they are shared across the entire ACE inhibitor class and partly because some are tied directly to the bradykinin mechanism that makes the drug work.

The ACE Inhibitor Cough

A persistent, dry, ticklish cough is the most recognizable side effect. It occurs in a meaningful minority of users, and it is thought to be caused by the same buildup of bradykinin that helps lower blood pressure. One study of patients who stopped enalapril because of cough found that their heightened cough sensitivity took up to four weeks to fully resolve, with the largest improvement happening by about two weeks.¹³ So if you develop a cough on enalapril and your doctor switches you to something else, the cough may linger a bit before disappearing. This side effect alone is one of the most common reasons people switch from an ACE inhibitor to an ARB (like losartan or valsartan), which blocks angiotensin II downstream without affecting bradykinin.

Angioedema

Rarely, ACE inhibitors can cause angioedema, a sudden swelling of the lips, tongue, throat, or face. This is also linked to bradykinin accumulation: when ACE is blocked, bradykinin levels rise, and in susceptible people the resulting increase in vascular permeability can lead to dramatic tissue swelling.¹⁴ Angioedema can be life-threatening if the airway is involved, so anyone who experiences sudden facial or throat swelling on enalapril should seek emergency care and will usually be switched to a different class of medication permanently.¹⁵

Potassium and Kidney Monitoring

Because enalapril suppresses aldosterone (the hormone that tells your kidneys to excrete potassium), potassium levels can rise. In most people the increase is modest and clinically unimportant. One large cohort study found that after starting an ACE inhibitor, roughly 0.7 percent of patients had an abnormally high potassium value on follow-up testing, while about 3 percent had an abnormal rise in creatinine, a marker of kidney function.¹⁶ The risk climbs when enalapril is combined with other drugs that also raise potassium, such as the diuretic spironolactone, which is commonly used alongside it in heart failure. In one study of patients taking both enalapril and spironolactone, roughly 12 percent developed potassium levels above 5.5 mEq/L during a year of treatment.¹⁷ This is why routine blood tests to check potassium and kidney function are standard practice when you start enalapril or change the dose.

In people who already have moderate to severe kidney impairment, enalapril can still be used, but close monitoring is essential. Studies have found that while enalapril suppresses aldosterone and raises potassium in this population, outright dangerous hyperkalemia can often be avoided with dose adjustments.¹⁸

Pregnancy and Enalapril

Enalapril should not be used during pregnancy, particularly after the first trimester. Exposure during the second and third trimesters has been strongly linked to reduced amniotic fluid, which in turn is associated with limb deformities, deficient skull bone formation, underdeveloped lungs, and neonatal kidney failure. These effects are thought to stem from the drug’s suppression of fetal kidney function, which normally contributes heavily to amniotic fluid production as pregnancy progresses.¹⁹ Women who are on enalapril and become pregnant, or who are planning to become pregnant, are typically switched to an alternative blood-pressure medication considered safer in pregnancy.

Enalapril Versus ARBs

Since angiotensin receptor blockers (ARBs) like losartan target the same hormonal system from a different point, they are frequently compared with enalapril. In heart failure, short-term trials have found the two classes to be broadly comparable in terms of exercise capacity, symptom control, and side effects.²⁰ ²¹ The main practical difference is that ARBs cause cough far less often because they do not raise bradykinin levels the way ACE inhibitors do. For many patients, the choice between the two comes down to tolerability: if you cough on enalapril, an ARB is usually the straightforward swap.

Where enalapril may still hold an edge is in specific post-heart-attack scenarios, where its remodeling-suppression effects have been shown to outperform losartan in at least one direct comparison.⁸ The evidence on this is not overwhelming, but it is one reason clinicians sometimes prefer ACE inhibitors over ARBs as the initial choice after a heart attack.

Combining Enalapril With Other Drugs

In practice, blood pressure is rarely managed with a single medication. Enalapril is often paired with a calcium-channel blocker like amlodipine, a thiazide diuretic, or both. In one trial of hypertensive patients who also had coronary artery disease, combining enalapril with amlodipine lowered blood pressure as effectively as amlodipine alone, with the added benefit of dramatically less ankle swelling, a common side effect of amlodipine on its own. Only about 7 percent of patients on the combination developed lower-leg edema, compared with about 31 percent of those on amlodipine alone.¹⁵

In heart failure, the drug landscape has shifted. A newer drug called sacubitril/valsartan combines an ARB with a neprilysin inhibitor, and it outperformed enalapril in the PARADIGM-HF trial for patients with reduced ejection-fraction heart failure. That trial is one reason enalapril is no longer automatically the first choice in that specific setting. However, the trial was designed with careful washout periods when transitioning patients between enalapril and the new drug, because combining ACE inhibition with neprilysin inhibition raises the risk of angioedema.²² If you are currently on enalapril and your doctor wants to switch you to sacubitril/valsartan, there will typically be a gap of at least 36 hours between stopping one and starting the other.

Enalapril in Children

Children with heart failure due to congenital heart disease or dilated cardiomyopathy sometimes receive enalapril, but it has historically been prescribed off-label in this population. A European research program developed a child-friendly formulation, an orodispersible minitablet, and ran studies in over 100 pediatric patients. The formulation appeared well tolerated and did not produce significant drug-related serious adverse events.²³

Dosing in children is not straightforward. Very young infants process enalapril differently: newborns under about 20 days of age showed dramatically higher blood levels of the active metabolite compared with older children at the same dose-per-kilogram, reflecting the immaturity of their kidneys and liver.²⁴ The evidence base for safe and effective prescribing in children remains limited, especially in younger age groups and in heart failure specifically, where some study results have been conflicting.²⁵

Why Genetics May Shape Your Response

Not everyone responds to enalapril the same way, and genetics appear to play a role both in how well it controls blood pressure and in whether you develop side effects like cough. A variation in the ACE gene known as the insertion/deletion polymorphism has received the most attention. A meta-analysis found that one version of this polymorphism significantly increased the risk of ACE inhibitor cough in East Asian populations, but not in people of European descent.²⁶ A separate meta-analysis pointed to the same genetic variation as an age-dependent predictor of cough risk.²⁷

On the effectiveness side, a pilot study found a strikingly strong association between carrying the D allele of the ACE gene and failing to reach target blood pressure on ACE inhibitor therapy. Among patients who achieved their target, the vast majority carried two copies of the I allele, while virtually all patients with two copies of the D allele did not reach target.²⁸ This was a small study and the effect size was unusually large, so it needs confirmation in bigger populations. But it fits into a broader trend in pharmacogenomics: the idea that genetic testing could someday help predict who will benefit most from a particular drug and who would do better with an alternative. For now, genetic testing before starting enalapril is not routine clinical practice, but the research hints at a future where it could be.